GX G6

Drug Profile

GX G6

Alternative Names: GLP1-hyFc; Glucagon-like peptide-1 long-acting - Genexine/Ildong; GX-G6

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genexine
  • Developer Genexine; Ildong Pharmaceutical
  • Class Glucagon-like peptides; Hormones; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetes mellitus

Most Recent Events

  • 07 Sep 2016 Phase-I clinical trials in Diabetes mellitus (Parenteral)
  • 16 Oct 2015 GX G6 licensed to Tasly in China
  • 08 Sep 2013 Preclinical development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top